Clinical Trial Update: IC14 (Atibuclimab) in Arrhythmogenic Cardiomyopathy [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/2 trial evaluating IC14 (Atibuclimab) in arrhythmogenic cardiomyopathy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Arrhythmogenic Cardiomyopathy
• Arrhythmogenic Left Ventricular Cardiomyopathy
• Arrhythmogenic Right Ventricular Cardiomyopathy

Drugs mentioned

• IC14

Snippet

Sponsor: Implicit Bioscience | Conditions: Arrhythmogenic Right Ventricular Dysplasia, Arrhythmogenic Left Ventricular Cardiomyopathy | Phase 1, Phase 2 | Status: COMPLETED